Japan's Shionogi & Co. believes its COVID-19 pill will easily garner $2 billion in annual sales if it secures U.S. approval, which the company expects to receive in late 2024, its chief executive said.
Xocova, a protease inhibitor like the COVID-19 treatments developed by Pfizer and Merck & Co., was granted emergency approval by Japanese regulators in November, making it the nation's first domestically produced oral treatment for COVID-19.
CEO Isao Teshirogi said that the drug — seen as the biggest of heavy bets by Shionogi on pandemic-related treatments — could be approved in South Korea and China as early as next month.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.